The chaperone-like activity of α-synuclein attenuates aggregation of its alternatively spliced isoform, 112-synuclein In Vitro: Plausible cross-talk between isoforms in protein aggregation

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Manda, Krishna Madhuri ^a,b   Yedlapudi, Deepthi ^b   Korukonda, Srikanth ^b   Bojja, Sreedhar ^b   Kalivendi, Shasi V ^a,b  

^a ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

112 SYNUCLEIN; ALPHA SYNUCLEIN; SYNUCLEIN; THIOFLAVINE; UNCLASSIFIED DRUG; ISOPROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PREDICTION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; UPREGULATION; WILD TYPE; ALTERNATIVE RNA SPLICING; CHEMISTRY; GENETICS; METABOLISM; PHYSIOLOGY; TEMPERATURE;

ALPHA-SYNUCLEIN; ALTERNATIVE SPLICING; HUMANS; PROTEIN ISOFORMS; SYNUCLEINS; TEMPERATURE;

EID: 84902504038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098657     Document Type: Article

References (50)

1. Beitz JM (2014) Parkinson's disease: a review. Front Biosci (Schol Ed). 1(6): 65-74.
2. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122(Pt 8): 1437-1448. (Pubitemid 29374122)
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645): 839-840.
4. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302(5646): 819-822. (Pubitemid 37339614)
5. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, et al. (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol. 152(2): 367-372. (Pubitemid 28106382)
6. Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, et al. (2004) Alpha synuclein and Parkinson's disease. FASEB J. 18(6): 617-626.
7. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95(11): 6469-6473. (Pubitemid 28249037)
8. Xia Y, Saitoh T, Ueda K, Tanaka S, Chen X, et al. (2001) Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms. J Alzheimers Dis. 3(5): 485-494. (Pubitemid 33031805)
9. Beyer K (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 112(3): 237-251.
10. Surguchov A (2013) Synucleins: are they two-edged swords? J Neurosci Res. 91(2):161-166.
11. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 273(16): 9443-9449. (Pubitemid 28183026)
12. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90(23): 11282-11286. (Pubitemid 23354413)
13. Han H, Weinreb PH, Lansbury PT Jr (1995) The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol. 2(3): 163-169.
14. Uversky VN (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem. 103(1): 17-37.
15. Levitan K, Chereau D, Cohen SI, Knowles TP, Dobson CM, et al. (2011) Conserved C-terminal charge exerts a profound influence on the aggregation rate of α-synuclein. J Mol Biol. 411(2): 329-333.
16. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc Natl Acad Sci U S A 97(9): 4897-4902. (Pubitemid 30238654)
17. Conway KA, Harper JD, Lansbury PT Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39(10): 2552-2563. (Pubitemid 30148907)
18. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97(2): 571-576. (Pubitemid 30070350)
19. Goldberg MS, Lansbury PT Jr (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol. 2(7): E115-E119.
20. Volles MJ, Lansbury PT Jr (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42(26): 7871-7878. (Pubitemid 36807703)
21. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, et al. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A 102(5): 1430-1435. (Pubitemid 40209187)
22. Hong DP, Xiong W, Chang JY, Jiang C (2011) The role of the C-terminus of human α-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers. FEBS Lett. 585(3): 561-566.
23. Hoyer W, Cherny D, Subramaniam V, Jovin TM (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43(51): 16233-16242. (Pubitemid 40041036)
24. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, et al. (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem. 280(24): 22670-22678. (Pubitemid 40853171)
25. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci. 32(3): 409-422.
26. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, et al. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42(28): 8530-8540. (Pubitemid 36875420)
27. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci U S A 103(6): 1661-1668.
28. McLean PJ, Hyman BT (2002) An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in α-synuclein aggregation. Neurosci Lett. 323(3): 219-223. (Pubitemid 34311916)
29. Beyer K, Domingo-Sàbat M, Humbert J, Carrato C, Ferrer I, et al. (2008) Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 9(3): 163-172.
30. Beyer K, Domingo-Sábat M, Lao JI, Carrato C, Ferrer I, et al. (2008) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9(1): 15-23. (Pubitemid 351170166)
31. Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, et al. (2006) Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport 17(12): 1327-1330. (Pubitemid 44337076)
32. Campion D, Martin C, Heilig R, Charbonnier F, Moreau V, et al. (1995) The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 26(2): 254-257.
33. Ueda K, Saitoh T, Mori H (1994) Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. Biochem Biophys Res Commun. 205(2): 1366-1372.
34. Beyer K, Ariza A (2013) α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol. 47(2): 509-524.
35. Kalivendi SV, Yedlapudi D, Hillard CJ, Kalyanaraman B (2010) Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson's disease. Free Radic Biol Med. 48(3): 377-383.
36. Mc Lean JR, Hallett PJ, Cooper O, Stanley M, Isacson O (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci. 49(2): 230-239.
37. Cardo LF, Coto E, de Mena L, Ribacoba R, Mata IF, et al. (2014) Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neurosci Lett. 562(6): 45-49.
38. Andrekopoulos C, Zhang H, Joseph J, Kalivendi S, Kalyanaraman B (2004) Bicarbonate enhances alpha-synuclein oligomerization and nitration: intermediacy of carbonate radical anion and nitrogen dioxide radical. Biochem J. 378(Pt 2) 435-447. (Pubitemid 38367234)
39. Kim TD, Paik SR, Yang CH, Kim J (2000) Structural changes in alpha-synuclein affect its chaperone-like activity in vitro. Protein Sci. 9(12): 2489-2496. (Pubitemid 32105731)
40. Kim TD, Paik SR, Yang CH (2002) Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41(46):13782-1379.
41. Uversky VN, Li J, Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem. 276(14): 10737-10744. (Pubitemid 38089246)
42. Antony T, Hoyer W, Cherny D, Heim G, Jovin TM, et al. (2003) Cellular polyamines promote the aggregation of alpha-synuclein. J Biol Chem. 278(5):3235-3240. (Pubitemid 36801235)
43. LeVine H 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309: 274-284.
44. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321): 2045-2047. (Pubitemid 27443610)
45. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 99(22): 14524-14529. (Pubitemid 35257704)
46. Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15(6): 916-926. (Pubitemid 32290778)
47. Ischiropoulos H (2003) Oxidative modifications of alpha-synuclein. Ann N Y Acad Sci. 991: 93-100.
48. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290(5493): 985-989.
49. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem. 275(24) 18344-18349. (Pubitemid 30414790)
50. McCarthy JJ, Linnertz C, Saucier L, Burke JR, Hulette CM, et al. (2011) The effect of SNCA 3′ region on the levels of SNCA-112 splicing variant. Neurogenetics 12(1): 59-64.